The significant differences in total cholesterol and Apo B as well as the trend in LDL concentrations are novel findings suggesting that compliant patients ingesting 300 mg/day of allopurinol may experience a decrease in lipid levels and reduction in heart disease risk. Here, APOB is linked to heart disorder.